Valuation
- Market cap
- 2,447,000
- Revenue TTM
- $4,490,000
- Net income TTM
- $-29,740,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -662.36%
- Debt to equity
- 0.00
Trading
- Volume
- 14,571,800
- Avg volume
- 3,131,146
- Day's range
- $0.09 – $0.11
- Shares out
- 26,006,000
- Stochastic %K
- 5%
- Beta
- 0.94
- Analysts
- Strong Sell
- Price target
- $7.00
Company profile
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanot...
Show more
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 609 495 2200
- Website
- https://palatin.com
- Address
- 11 Deer Park Drive, Suite 204, Monmouth Junction, United States
Latest news
No headlines yet.
